Video

Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial

Author(s):

Jeanny B. Aragon-Ching, MD, FACPSrikala Sridhar, MD, MSc, FRCPC

Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.

Related Videos
Guru P. Sonpavde, MD
Guru P. Sonpavde, MD
Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute
John K. Lee, MD, PhD
Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute
Dingwei Ye, MD, PhD
Dingwei Ye, MD, PhD
Terence W. Friedlander, MD
Joshua Linscott, MD, PhD
Terence W. Friedlander, MD,
Related Content
Jacqueline Brown, MD, of Winship Cancer Institute
October 15th 2024

ADCs Usher in a Complex New Era of Disease and Toxicity Management in Bladder Cancer

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Jacqueline Brown, MD, of Winship Cancer Institute
October 10th 2024

Enfortumab Vedotin Plus Pembrolizumab Stands Strong as the Frontline Bladder Cancer SOC

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Andrea B. Apolo, MD
September 25th 2024

Adjuvant Pembrolizumab Prolongs DFS Regardless of PD-L1 or Nodal Status in High-Risk MIBC

Dingwei Ye, MD, Fudan University Shanghai Cancer Center
September 24th 2024

BL-B01D1 Shows Preliminary Efficacy, Safety in Pretreated Advanced Urothelial Carcinoma